Effects of “Legal X” Piperazine Analogs on Dopamine and Serotonin Release in Rat Brain
Open Access
- 1 October 2004
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1025 (1) , 189-197
Abstract
Abstract: 3,4‐Methylenedioxymethamphetamine (MDMA) is a popular illicit drug that evokes transporter‐mediated release of serotonin (5‐HT) and dopamine (DA) from nerve cells. Recently, drug users have ingested combinations of the piperazine analogs, 1‐benzylpiperazine (BZP) and 1‐(m‐trifluoromethylphenyl)piperazine (TFMPP), in an attempt to mimic the subjective effects of MDMA. In the present study, we compared neurochemical effects of MDMA, BZP, and TFMPP in rat brain. The ability of MDMA, BZP, and TFMPP to stimulate efflux of [3H]5‐HT and [3H]MPP+ (a DA transporter substrate) was determined in vitro using release assays in synaptosomes. The ability of these drugs to increase extracellular 5‐HT and DA in vivo was assessed using intracranial microdialysis in nucleus accumbens. MDMA stimulated transporter‐mediated release of 5‐HT (EC50= 58 nM) and MPP+ (EC50= 119 nM). BZP was a selective releaser of MPP+ (EC50= 175 nM), whereas TFMPP was a selective releaser of 5‐HT (EC50= 121 nM). MDMA injections (1 and 3 mg/kg, i.v.) increased dialysate 5‐HT and DA in a dose‐related manner, but actions on 5‐HT were predominant. BZP (3 and 10 mg/kg, i.v.) elevated dialysate DA and 5‐HT, while TFMPP (3 and 10 mg/kg, i.v.) elevated only 5‐HT. The coadministration of BZP plus TFMPP (BZP/TFMPP) produced marked elevations in extracellular 5‐HT and DA that mirrored the effects of MDMA. At the high dose of BZP/TFMPP (10 mg/kg, i.v.), the rise in dialysate DA exceeded the summed effects of the drugs alone. Our results support the hypothesis that the BZP/TFMPP combination mimics the neurochemical mechanism of MDMA, providing a basis for recreational use of these agents. Additionally, the findings suggest possible drug‐drug synergism when piperazine drugs are coadministered at high doses.Keywords
This publication has 22 references indexed in Scilit:
- The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)Pharmacological Reviews, 2003
- 1-(m-Chlorophenyl)piperazine (mCPP) Dissociates In Vivo Serotonin Release from Long-Term Serotonin Depletion in Rat BrainNeuropsychopharmacology, 2001
- Reinforcing Effects of MDMA (‘Ecstasy’) in Drug-Naive and Cocaine-Trained RatsPharmacology, 2001
- Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy VolunteersNeuropsychopharmacology, 1998
- Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy VolunteersNeuropsychopharmacology, 1998
- Carrier‐Mediated Release of Serotonin by 3,4‐Methylenedioxymethamphetamine: Implications for Serotonin‐Dopamine InteractionsJournal of Neurochemistry, 1996
- Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake ratsNeuropharmacology, 1993
- Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudatePharmacology Biochemistry and Behavior, 1991
- Substituted piperazine and indole compounds increase extracellular serotonin in rat diencephalon as determined by in vivo microdialysisNeuropharmacology, 1991
- 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptaminePharmacology Biochemistry and Behavior, 1991